Edmund K Waller MD

Hematologic Oncology

Professor of Hematology & Oncology, Emory University

1365 Clifton Rd NEAtlanta, GA 30322
Phone+1 404-727-4995

Dr. Waller is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Waller's full profile Already have an account?

Summary

Edmund Waller, MD, is an oncology specialist based in Atlanta, GA, with a subspecialty in hematologic oncology. He completed his residency in internal medicine and a fellowship in medical oncology at Stanford Health Care, after earning his medical degree from Weill Cornell Medicine and a PhD in Chemical Biology from Rockefeller University. Dr. Waller has served as a professor at Emory Clinic since 1994 and has substantial experience in treating non-Hodgkin lymphoma and acute myeloid leukemia. His research is well-documented in numerous publications in leading journals such as The Journal of Biological Chemistry and Blood. He has played significant roles in various clinical trials, including those focused on CAR T cell therapy and graft-vs-host disease. Dr. Waller's accolades include being a fellow of the National Academy of Inventors and the American Association for the Advancement of Science, as well as being consistently recognized as one of America's Top Doctors by Castle Connolly.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1988 - 1993
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1985 - 1988
Weill Cornell MedicineClass of 1985
Rockefeller UniversityPhD, Chemical Biology, 1978 - 1984
Harvard UniversityAB, Biology, Magna Cum Laude, 1974 - 1978

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1987 - Present
GA State Medical License 1995 - 2027
TX State Medical License 1993 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow American Association for the Advancement of Science American Association for the Advancement of Science, 2025
Fellow National Academy of Inventors National Academy of Inventors, 2025
America's Top Doctors for Cancer Castle Connolly, 2011-2022

Clinical Trials

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
COMPLETED
PHASE3
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
COMPLETED
PHASE3
A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation
TERMINATED
PHASE2

Publications & Presentations

PubMed

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
Joseph P McGuirk, Armin Ghobadi, Carlos R Bachier, Paul J Shaughnessy, Farrukh Awan
Blood Advances. 2026-09-08
Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients.
Caspian H Oliai, Arpita Gandhi, Rasmus T Hoeg, Lori Muffly, Samer A Srour
Transplantation and Cellular Therapy. 2026-08-21
Vancomycin-Tacrolimus Combination-Related Acute Kidney Injury Risk in Posthematopoietic Stem Cell Transplant Patients.
Tuisha Gupta, Yuan Liu, Kevin Hall, Minal J Surati, Edmund K Waller
Transplantation and Cellular Therapy. 2026-08-01

Journal Articles

The Potential of CAR T Cell Therapy in Pancreatic Cancer
Mehmet Akce, Mohammad Y Zaidi, Edmund K Waller, Frontiers in Neurology
Recipient Single Nucleotide Polymorphisms in Paneth Cell Antimicrobial Peptide Genes and Acute Graft‐Versus‐Host Disease: Analysis of BMT CTN‐0201 and ‐0901 Samples
Armin Rashidi, Edmund K Waller, Bharat Thyagarajan, Claudio Anasetti, Daniel J Weisdorf, Bart L Scott, Bruce R Blazar, British Journal of Haematology
Indoles Derived from Intestinal Microbiota Act via Type I Interferon Signaling to Limit Graft-Versus-Host-Disease
Edmund K Waller, Zachariah DeFilipp, Muna Qayed, Akshay Sharma, Blood

Abstracts/Posters

Outcomes of Elderly Patients Undergoing Allogeneic Transplantation for Acute Myeloid Leukemia with Fludarabine/Melphalan or Fludarabine/TBI Conditioning Regimen
Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...
Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
IMPACT-TB*: A Phase II Trial Assessing the Capacity of Low Dose Imatinib to Induce Myelopoiesis and Enhance Host Anti-Microbial Immunity Against Tuberculosis. *Imatini...
Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023

Press Mentions

Research Roundup: Recent Grants and Publications for Emory Faculty and StaffMarch 10th, 2022
Research Roundup: Recent Grants and Publications for Emory Faculty and StaffSeptember 21st, 2021
NIAID Supports Clinical Testing of Anti-Cancer Drug for TBAugust 15th, 2017

Grant Support

Targeting VIP–VPAC Signaling to Reverse Immune Exclusion and Enhance Immunotherapy Response in Pancreatic CancerEMORY UNIVERSITY2026–2031
BMT Core: Southeast Bone Marrow Transplant ConsortiumEMORY UNIVERSITY2024–2031
BMT Core: Southeast Bone Marrow Transplant ConsortiumEMORY UNIVERSITY2024–2031
Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancerEMORY UNIVERSITY2024–2029
Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancerEMORY UNIVERSITY2024–2029